Verification of the performance of the BD MAX Check-Points CPO Assay on clinical isolates

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

The BD MAX Check-Points CPO Assay (BD MAX CPO Assay; BD, The Netherlands) is a diagnostic test designed for the rapid detection and differentiation of the blaKPC, blaNDM, blaVIM/blaIMP-1, and blaOXA-48 genes. We verified the performance of the BD MAX CPO Assay to implement it in the clinical laboratory. A total of 113 bacterial isolates collected from various clinical specimens harboring carbapenemase genes as confirmed by polymerase chain reaction (PCR) and sequencing were evaluated. The results of the BD MAX CPO Assay were compared to previously confirmed results. All results of the BD MAX CPO Assay were concordant with previous results; 61 Klebsiella pneumoniae carbapenemase (KPC), 40 New Delhi metallo-β-lactamase (NDM), three oxacillinase-48 (OXA-48)-like, two imipenem (IMP), and four multiple carbapenemase genes (one KPC/NDM, three NDM/OXA) were detected by the BD MAX CPO Assay. Three non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae isolates were negative. The BD MAX CPO Assay can be used to identify carbapenemase gene in bacterial isolates cultured from clinical specimens in the clinical laboratory.

Original languageEnglish
Pages (from-to)165-168
Number of pages4
JournalJournal of Laboratory Medicine
Volume44
Issue number3
DOIs
StatePublished - 1 Jun 2020

Keywords

  • BD MAX Check-Points CPO Assay
  • carbapenemase
  • Enterobacteriaceae
  • real-time PCR

Fingerprint

Dive into the research topics of 'Verification of the performance of the BD MAX Check-Points CPO Assay on clinical isolates'. Together they form a unique fingerprint.

Cite this